Neurocrine Biosciences | NBIX - النقدية وما يعادلها





النقدية وما يعادلها تغيير تاريخ
AbbVie USD 5.23B 400M 2025-12
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
Agios Pharmaceuticals USD 113.6M 24.47M 2026-03
ALKERMES USD 351.55M 37.02M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Amgen USD 12.04B 2.91B 2026-03
Biogen USD 3.38B 374.2M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Cytokinetics USD 129.84M 7.32M 2026-03
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Exelixis USD 482.49M 106.19M 2025-12
Gilead Sciences USD 7.56B 234M 2025-12
Halozyme Therapeutics USD 133.82M 285.84M 2025-12
Incyte USD 4.02B 435.22M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Pfizer USD 1.7B 561M 2026-03
Prothena USD 307.53M 23.31M 2025-12
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Repligen USD 566.02M 182.73M 2025-12
Rigel Pharmaceuticals USD 48.53M 4.87M 2025-09
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
Teva Pharmaceutical Industries USD 3.56B 1.35B 2025-12
Ultragenyx Pharmaceutical USD 421M 218.49M 2025-12
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03
Xoma USD 143.9M 7.68M 2024-06